Fibromyalgia

Fibromyalgia Treatment | Ketamine for Fibromyalgia

Fibromyalgia takes years to diagnose and a lifetime to explain to people who have not had it. The pain is real, the fatigue is real, and the cognitive fog that makes a grocery list feel like a research paper is real. It does not show up on imaging. It does not bleed into a test tube. For decades, that invisibility was used to suggest it might not exist. It does. It is a real, diagnosable, neurobiological condition. And for patients who have tried the approved medications, the lifestyle modifications, and the physical therapy and are still in significant daily pain, fibromyalgia ketamine treatment is one option worth understanding in clinical terms.

Allay Health and Wellness offers fibromyalgia ketamine treatment in Palm Beach Gardens, Florida, as an off-label clinical service for adults with fibromyalgia who have not found adequate relief through established care. This page covers what fibromyalgia is at a neurobiological level, why it is difficult to treat, where fibromyalgia ketamine treatment fits, what the evidence shows, and who may be a candidate for evaluation.

What Fibromyalgia Is at a Neurobiological Level

Fibromyalgia is characterized by widespread musculoskeletal pain, fatigue, sleep disruption, and cognitive difficulties, often referred to as fibro fog. The American College of Rheumatology criteria require widespread pain in all four body quadrants present for at least three months, with a minimum number of symptomatic regions. But the most clinically meaningful advance in understanding fibromyalgia has come from neuroimaging research showing that it is not a peripheral tissue disorder. It is a disorder of central sensitization.

Central sensitization is a state in which the central nervous system becomes amplified in its processing of pain signals. The gain on the system is turned up. Stimuli that would not normally be painful become painful. Stimuli that are mildly painful become severely so. The nervous system is not responding to pain correctly; it is generating pain from signals that should not reach the threshold of pain at all. This mechanistic understanding is what makes fibromyalgia ketamine treatment more than an empirical guess. It is a targeted intervention at a specific neurobiological failure point. This understanding matters enormously for fibromyalgia ketamine treatment, because it explains why ketamine’s mechanism is particularly relevant here. Most chronic pain treatments were designed before central sensitization was well understood, and they target peripheral tissue and spinal cord pathways rather than the central amplification that defines fibromyalgia. Fibromyalgia ketamine treatment is designed around a different model of the problem. The National Institute of Neurological Disorders and Stroke maintains information on fibromyalgia and central pain sensitization that gives patients context for this neurobiological framing.

Why Fibromyalgia Is Difficult to Treat

Most pain treatments are designed for peripheral tissue damage. Anti-inflammatories reduce inflammation. Opioids alter pain signaling through opioid receptors. These mechanisms do not directly address the altered central pain processing associated with fibromyalgia. This is one reason fibromyalgia may not respond to treatments that help other pain conditions, leaving some patients cycling through medications without adequate symptom improvement. The FDA-approved medications for fibromyalgia are pregabalin, duloxetine, and milnacipran. All three act on the central nervous system rather than simply targeting peripheral tissue. However, treatment response varies, and some patients experience incomplete symptom relief or side effects that make continued use difficult.

Complementary approaches, including aerobic exercise, cognitive behavioral therapy for chronic pain, sleep hygiene, and mindfulness-based stress reduction, can also form part of comprehensive fibromyalgia care. Patients pursuing fibromyalgia ketamine treatment are not expected to abandon these approaches. Instead, infusion treatment may be considered within a broader chronic pain management plan. Because fibromyalgia can also occur alongside depression or anxiety, appropriate mental health care may become another important part of a coordinated treatment strategy.

Why Ketamine’s Mechanism Is Specifically Relevant to Fibromyalgia

This is where fibromyalgia ketamine treatment has a stronger mechanistic argument than for many other conditions. Ketamine is a potent NMDA receptor antagonist. NMDA receptors play a central role in the process of central sensitization. The wind-up phenomenon, in which repeated sub-threshold stimuli progressively lower the pain threshold, is mediated in part through NMDA receptor activation. By blocking NMDA receptors, ketamine directly interrupts one of the primary mechanisms by which central sensitization is maintained. This is a different mechanism from pregabalin, which acts on voltage-gated calcium channels, and from duloxetine and milnacipran, which act on serotonin and norepinephrine reuptake. For patients whose fibromyalgia has not responded to these approaches, ketamine targets a different point in the same central sensitization pathway rather than offering another variation of what has already failed.

Published research on fibromyalgia ketamine treatment is limited but meaningful. Small studies and case series have found that IV ketamine infusions can produce significant reductions in pain intensity in fibromyalgia patients, with effects persisting beyond the acute drug period in a subset of patients. A review in Pain Medicine noted that ketamine reduced pain in fibromyalgia patients when given intravenously, with some patients reporting clinically significant improvement lasting weeks to months after a course of infusions, though the authors emphasized the need for larger controlled trials.

The Off-Label Reality

Fibromyalgia ketamine treatment is an off-label use. The FDA has not approved IV ketamine for fibromyalgia or for any chronic pain condition. Ketamine’s only FDA-approved indication is as a general anesthetic. Spravato (esketamine) is not approved for fibromyalgia either. Its approval covers treatment-resistant depression in adults and depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior. It is not used at Allay Health and Wellness for pain conditions of any kind.

Off-label prescribing by a licensed clinician is legal and standard across medicine, and many of the most meaningful advances in chronic pain management involve off-label pharmacological approaches. However, patients pursuing fibromyalgia ketamine treatment should understand the regulatory status, the limitation of the evidence base, and the realistic range of possible outcomes before any treatment begins. This is a conversation we have thoroughly with every patient at intake.

Risks and Side Effects of Fibromyalgia Ketamine Treatment

Every patient evaluated for fibromyalgia ketamine treatment at Allay Health & Wellness receives a clear explanation of potential risks, side effects, and treatment limitations before anything is scheduled.

• Dissociation: Ketamine can cause temporary changes in perception, awareness, time, space, or sense of self. Clinical staff monitor these effects throughout every infusion.
• Sedation: Ketamine may cause sedation and impaired alertness. You may not drive after a session, and a responsible adult must provide transportation home.
• Blood Pressure and Heart Rate Changes: Temporary increases in blood pressure and heart rate can occur. Vital signs are monitored before, during, and after every session.
• Nausea and Dizziness: These effects may occur during or after treatment. For longer pain-management infusions, clinicians may consider appropriate measures to manage nausea based on individual needs.
• Psychological Effects: Some patients experience vivid perceptual changes, anxiety, or heightened emotional responses. Clinical staff remain present throughout every infusion to monitor and support patients.
• Controlled Substance Considerations: Ketamine is a federally regulated Schedule III controlled substance. Dependency and misuse risks are considered during evaluation, particularly when ongoing treatment may be contemplated. Understanding whether ketamine can be addictive and how supervised use affects that risk is an important part of informed treatment planning.

No outcome from fibromyalgia ketamine treatment can be predicted or guaranteed. Individual responses vary, and clinical evidence for ketamine specifically for fibromyalgia remains limited. Allay Health & Wellness discusses these limitations openly so patients can make informed decisions before proceeding.

Fibromyalgia, Depression, and the Shared Neurobiology

This connection deserves direct attention because it shapes how fibromyalgia ketamine treatment is evaluated and positioned. Fibromyalgia and major depressive disorder co-occur at rates substantially higher than chance. Both involve changes in central nervous system processing, both can disrupt sleep, and both involve complex neurotransmitter systems. Whether depression in patients with fibromyalgia develops partly from living with chronic pain, reflects overlapping biological mechanisms, or involves a combination of factors is not always clear.

What matters clinically is that ketamine’s effects on mood may be relevant when fibromyalgia occurs alongside depression. Changes in mood, sleep, anxiety, and pain perception can influence how patients experience their overall symptom burden. For this reason, fibromyalgia ketamine treatment may require clinicians to consider pain and psychiatric symptoms separately rather than assuming that improvement in one will necessarily improve the other. For patients experiencing significant depression alongside fibromyalgia, ketamine therapy for depression may become part of the broader clinical discussion, while co-occurring anxiety requires its own evaluation when considering ketamine therapy for anxiety. Daniel Cartledge, M.D., our clinical consultant, is double board-certified in pain management and physical medicine and rehabilitation, bringing relevant experience to patients whose pain and psychiatric concerns overlap. Patients can also learn more about the backgrounds and credentials of the Allay Health & Wellness clinical team before deciding whether to schedule an evaluation.

What Fibromyalgia Ketamine Treatment Involves at Allay

Every patient considering fibromyalgia ketamine treatment at Allay Health & Wellness begins with a clinical evaluation before treatment is recommended. The process includes reviewing your medical and pain history, discussing the infusion experience, monitoring you throughout treatment, and providing clear aftercare instructions.

• Evaluation: Intake covers your fibromyalgia diagnosis and symptom history, medications previously tried with doses and durations, current pain management regimen, co-occurring psychiatric conditions, cardiovascular health, substance use history, and current providers. No referral is required. Bringing your available clinical records can help our team complete a more informed evaluation.
• The Sessions: IV ketamine is administered slowly through an intravenous line in a private, monitored room. A licensed clinician remains present, and vital signs are monitored throughout. Pain protocols may differ in duration and dosing from psychiatric protocols. For fibromyalgia ketamine treatment, the number and frequency of infusions are individualized according to your clinical presentation and response. During your consultation, we explain how many ketamine therapy sessions may be needed, how a treatment course is structured, and why pain-management protocols can differ from psychiatric treatment schedules.
• After Sessions: You may not drive after an infusion. A responsible adult must arrange transportation home, and you should follow the individualized post-treatment instructions provided by your clinical team.

Who May Be a Candidate

A clinical evaluation is required before any treatment recommendation at Allay. Adults who may be appropriate candidates for fibromyalgia ketamine treatment typically present with the following:

A fibromyalgia diagnosis from a licensed clinician, with documented history of inadequate response to at least two treatments including at least one FDA-approved fibromyalgia medication at an adequate dose and duration. Active engagement with or willingness to engage with non-pharmacological fibromyalgia management including aerobic exercise, sleep optimization, and psychological support, since ketamine is most effective within a comprehensive pain management plan rather than as a standalone intervention. Patients who combine infusion treatment with behavioral and lifestyle approaches generally have more to work with than those relying on the infusion alone. Absence of medical contraindications including uncontrolled hypertension, unstable cardiovascular conditions, or active psychosis.

Substance use history is evaluated carefully because ketamine is a Schedule III controlled substance. A history of substance use does not automatically disqualify anyone but is a clinically significant factor in treatment planning. Allay Health and Wellness treats adult patients 18 years and older exclusively.

FAQs about Fibromyalgia Ketamine Treatment

1. Is ketamine FDA-approved for fibromyalgia?
   No. Fibromyalgia ketamine treatment is an off-label use. The FDA has not approved IV ketamine for fibromyalgia or any chronic pain condition. The approved medications for fibromyalgia include pregabalin, duloxetine, and milnacipran. These established options are generally considered before off-label treatments.
2. Why might ketamine work for fibromyalgia when other medications have not?
   Fibromyalgia involves central sensitization, which is associated in part with NMDA receptor activity. Ketamine is an NMDA receptor antagonist, so it acts through a different mechanism than most standard fibromyalgia medications. This different mechanism provides a clinical rationale for considering ketamine in selected patients who have not responded adequately to established treatments.
3. How long do the effects of fibromyalgia ketamine treatment last?
   The duration varies considerably between patients. Some patients may experience pain reduction lasting weeks or longer after a series of infusions, while others may require additional treatment or experience limited improvement. No specific duration or outcome can be predicted before treatment begins.
4. Does insurance cover fibromyalgia ketamine treatment?
   Off-label IV ketamine is generally not covered by most insurance plans. Allay Health & Wellness accepts Medicare, Cigna, UnitedHealthcare, and Aetna for eligible services. Our team verifies benefits and provides a cost summary before sessions are scheduled. Coverage varies by plan and is never guaranteed.
5. Is fibromyalgia ketamine treatment the same as the psychiatric protocol?
   Not necessarily. Pain protocols for fibromyalgia may involve different infusion durations, dosing, or treatment schedules than psychiatric protocols used for conditions such as depression. Your clinician will determine an appropriate protocol based on your diagnosis, medical history, previous treatments, and individual clinical needs.
6. Do I need a referral?
   No referral is required. Bring documentation of your fibromyalgia diagnosis, information about previous medications including doses and durations, and details of your current pain management regimen. This information helps the clinical team conduct a complete evaluation.

Schedule a Consultation for Fibromyalgia Treatment

If fibromyalgia symptoms have not improved adequately with established treatments, Allay Health & Wellness is available to discuss whether additional treatment options may be appropriate for your individual situation. Our clinical team begins with a comprehensive evaluation, reviews your previous care, and explains the available evidence, potential risks, limitations, and realistic expectations before making any treatment recommendation.

You can learn more about the clinicians involved in your care and review the peer-reviewed research that informs our approach before deciding whether to proceed. If you have questions about eligibility, treatment expectations, safety, costs, or your existing fibromyalgia care, our team can address them during your consultation. Allay Health & Wellness treats adults aged 18 and older exclusively.

Address: 11000 Prosperity Farms Rd, Suite 101, Palm Beach Gardens, FL 33410
Email: [email protected]
Phone: (561) 421-6444

Contact Allay Health & Wellness to schedule a consultation and discuss your treatment options with our clinical team.

Medical Disclaimer: This content is educational only and not a substitute for professional medical advice, diagnosis, or treatment. IV ketamine for fibromyalgia is an off-label use, not FDA-approved for fibromyalgia or any chronic pain condition. Spravato is not approved for fibromyalgia or pain. FDA-approved fibromyalgia medications including pregabalin, duloxetine, and milnacipran should be tried before off-label options. Individual outcomes vary and are never guaranteed. Treatment requires evaluation by a licensed clinician. Allay treats adults 18 and older.

Reviewed by Nicholas Marino, MBA, Co-Founder and CEO, Allay Health and Wellness